Quote:

---

79% of Crohn's disease patients in remission after early intervention

Led by researchers from the University of Cambridge in the UK, a clinical trial examined the effectiveness of giving the immunotherapy drug infliximab earlier, as soon as possible after diagnosis. They employed what’s called a ‘top-down’ strategy, meaning the drug was given straight after diagnosis regardless of the patient’s symptom severity.

Infliximab is a monoclonal antibody that enhances and improves the immune system by blocking tumor necrosis factor alpha (TNF-alpha), a protein cells produce during acute inflammation. The drug is injected intravenously into the bloodstream or under the skin. Although due to historical concerns about infliximab’s cost and side effects – including an increased risk of infection due to suppression of the immune system

https://newatlas.com/medical/crohns-disease-treatment/

---

I wonder what drug downregulates TNF-a and is not an immune suppressor. Why infliximab is an immune suppressor and leronlimab is not is because infliximab blocks it completely. Leronlimab on the other hand allows the other receptors to upregulate it to a homeostatic level.